Thrombolytic Science International

Executive Summary

Thrombolytic Science International (TSI) is a private biopharmaceutical company focused on transforming the treatment of thrombotic diseases, particularly ischemic stroke. Its lead candidate is an intravenous (IV) therapy designed to restore blood flow rapidly, enabling treatment to be administered closer to the time of symptom onset rather than requiring patient transport to specialized centers. This approach addresses a critical unmet need, as timely thrombolysis is essential for improving outcomes in stroke. Currently in Phase 2 clinical development, TSI aims to demonstrate the safety and efficacy of its drug in a broader patient population. With a differentiated value proposition—bringing the drug to the patient instead of the patient to the drug—TSI has the potential to significantly expand access to life-saving therapy. The company was founded in 2003 and is based in Cambridge, MA. Its pipeline details are limited, but the Phase 2 status indicates progress toward clinical validation. Success in upcoming trials could position TSI as a key player in acute stroke care, addressing a large global market. The company remains privately held, with no disclosed funding or valuation, and operates in the small molecules category.

Upcoming Catalysts (preview)

• Q2 2027Phase 2 Top-Line Data Readout50% success
• Q4 2026FDA Fast Track Designation70% success
• Q2 2027Strategic Partnership or Licensing Agreement40% success